Latest Healthcare News

Page 13 of 197
Anatara Lifesciences will manufacture an approximately 10,000-capsule demonstration batch of its AOC anti-obesity compound after deciding further pre-clinical work and an immediate clinical trial are not required. The company ended September with $551,000 in cash, helped by a $318,402 R&D tax rebate.
Ada Torres
Ada Torres
13 Oct 2026
Bailador Technology Investments reported $28 million in FY26 cash realisations and 32% weighted revenue growth across its portfolio, while profit after tax fell to $6.9 million. The technology investment fund also reaffirmed its fully franked dividend strategy despite a 7.5% gross portfolio return that fell short of internal targets.
Claire Turing
Claire Turing
13 Oct 2026
Orthocell says Remplir was placed successfully in five complex robotic prostatectomy cases, with no device-related complications reported over approximately 12 months. The preliminary results will guide a larger prospective trial ahead of a planned US expansion for the nerve repair product.
Ada Torres
Ada Torres
13 Oct 2026
Vitura Health has opened FY2027 with a sharp improvement in EBITDA and lower operating costs, while revenue growth continued across its digital health businesses. The figures are unaudited, and the company still needs to prove that the improvement can survive the wind-down of Bupa-related telehealth volumes.
Ada Torres
Ada Torres
13 Oct 2026
Stakk’s unaudited pro-forma revenue rose 16.5% to A$16.1 million in the first quarter of FY2027, implying an illustrative annualised pace above its full-year objective. The company has kept its A$55.2 million revenue and A$18.5 million EBITDA targets unchanged, stressing that one quarter does not establish the year.
Victor Sage
Victor Sage
12 Oct 2026
Acrux says the FDA has confirmed the evidence package required to take its female testosterone spray into Phase III trials for postmenopausal women with HSDD. The agency also indicated the company may apply for three years of data exclusivity if the product reaches submission.
Ada Torres
Ada Torres
12 Oct 2026
Firebrick Pharma has raised approximately $732,000 from strategic investors, with its Philippines licensing partner investing $631,750 to lift its holding above 10%. The funding will support US retail production, a Singapore product launch and working capital.
Ada Torres
Ada Torres
12 Oct 2026
Ryman Healthcare’s retirement village resales reached an eight-quarter high in the second quarter, while aged care occupancy climbed to 94%. The operating update also shows new-sales inventory continuing to decline as the company positions for stronger recurring earnings.
Ada Torres
Ada Torres
12 Oct 2026
Emyria’s FY26 annual report shows a rapidly expanding psychedelic-assisted care network, with revenue up 210% and treatment capacity reaching 18 beds across four states. The gains came alongside a larger loss, $4.6 million in operating cash outflow and an auditor-highlighted material uncertainty over the company’s ability to continue without further funding.
Victor Sage
Victor Sage
9 Oct 2026
Medical Developments International returned to EBIT profitability in FY26 as Penthrox volumes strengthened across Australian hospitals and Europe. The company now faces the less glamorous test of converting regulatory progress into repeatable demand while absorbing weaker Respiratory sales and new amortisation costs.
Ada Torres
Ada Torres
9 Oct 2026
Australian Ethical Investment delivered record funds under management and a 29% rise in shareholder profit in FY26, despite weak performance from Australian equities and emerging companies. The ASX-listed ethical fund manager also increased its fully franked dividend and set out a growth plan centred on private markets, superannuation and technology.
Claire Turing
Claire Turing
9 Oct 2026
Genetic Signatures reduced its quarterly operating cash outflow to A$1.0 million after restructuring, while commercial testing began under its Danish hospital contract. The company is also advancing an all-scrip Microba merger, but faces a contested shareholder meeting later this month.
Ada Torres
Ada Torres
8 Oct 2026

Browse the archive

Full archive